Name (Synonyms) | Correlation | |
---|---|---|
drug642 | ChAdOx1 nCoV-19 plus 5x10^10vp boost (qPCR) Wiki | 1.00 |
drug2978 | Two dose MenACWY vaccine Wiki | 1.00 |
drug638 | ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Wiki | 1.00 |
drug637 | ChAdOx1 nCoV-19 (Abs 260) Wiki | 1.00 |
drug1723 | MenACWY vaccine Wiki | 1.00 |
drug639 | ChAdOx1 nCoV-19 (qPCR) Wiki | 1.00 |
drug643 | ChAdox1 n-CoV-19 (Abs 260) vaccine low dose Wiki | 1.00 |
drug2979 | Two dose MenACWY vaccine 4-12 weeks Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
During the last couple of years, a growing number of wearable devices evolved to provide accurate, cheap and non-invasive monitoring of vitals parameters.This connected care technology could be helpful for treatment and care during a pandemic such as COVID-19. The use of these non-invasive remote monitoring devices can help health care providers to assess patient's vital signs and symptom progression, reducing reducing patient and healthcare provider contact and exposure to COVID-19 during this pandemic.
Description: The primary outcome is the assessment of mean bias (± 95% CI or precision of bias) for systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) between invasive and non-invasive BP measurements. The standard deviation of the bias (±95% limits of agreement), will be assessed for SBP, DBP, and MBP measurements.
Measure: Feasibility of non-invasive BP monitors: blood pressure Time: 10 to 15 minutes per patient (once)Description: Secondary outcomes include reliability index (Qualification Index QI) for blood pressure epochs and count of qualified epochs.
Measure: Percentage of signal with artefact, Time: 10 to 15 minutes per patient (once)